Kala Bio (KALA) Retained Earnings (2016 - 2026)
Kala Bio (KALA) posted Retained Earnings of $707.3 million for Q1 2026, up 201.78% sequentially from -$694.9 million in Q4 2025, and up 204.49% YoY from $232.3 million in Q1 2025.
Kala Bio (KALA) Retained Earnings (2016 - 2026) Analysis & Trends
Kala Bio has reported Retained Earnings for 11 years, with the latest figure at $707.3 million in Q1 2026.
- Quarterly Retained Earnings rose 204.49% year-over-year to $707.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $707.3 million (up 204.49% YoY) and the FY2025 annual result came in at -$694.9 million, down 4.04% from the prior year.
- Retained Earnings grew to $707.3 million in Q1 2026 per KALA's latest filing, from -$694.9 million in the prior quarter.
- Over five years, Retained Earnings peaked at $707.3 million in Q1 2026 and troughed at -$695.6 million in Q3 2025.
- A 5-year average of -$207.0 million and a median of -$629.4 million in 2023 frame the typical range for Retained Earnings.
- The sharpest annual moves came in 2023 and 2024: Retained Earnings jumped 62955900.0% in 2023, then plunged 65974600.0% in 2024.
- Over 5 years, Retained Earnings stood at $606.2 million in 2022, then sank by 203.83% to -$629.4 million in 2023, then retreated by 6.12% to -$667.9 million in 2024, then retreated by 4.04% to -$694.9 million in 2025, then jumped by 201.78% to $707.3 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $707.3 million, -$694.9 million, and -$695.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 4.38 Bn |
| 10 | Kala Bio | 9.97 Mn | 9.97 Mn | - | 707.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 707.26 Mn |
| Dec 31, 2025 | -694.90 Mn |
| Sep 30, 2025 | -695.59 Mn |
| Jun 30, 2025 | -688.02 Mn |
| Mar 31, 2025 | -676.87 Mn |
| Dec 31, 2024 | -667.92 Mn |
| Sep 30, 2024 | -659.75 Mn |
| Jun 30, 2024 | -650.80 Mn |
| Mar 31, 2024 | -641.22 Mn |
| Dec 31, 2023 | -629.41 Mn |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 629.56 Mn |
| Mar 31, 2023 | -601.67 Mn |
| Dec 31, 2022 | 606.18 Mn |
| Sep 30, 2022 | 573.40 Mn |
| Jun 30, 2022 | -1,000.00 |
| Mar 31, 2022 | 569.97 Mn |
| Dec 31, 2021 | -542.39 Mn |
| Sep 30, 2021 | -494.82 Mn |
| Jun 30, 2021 | -466.69 Mn |